Skip to main content
NCBI home page
Health Services Research logoLink to Health Services Research
. 1996 Apr;31(1):5–19.

Practice setting and physician influences on judgments of colon cancer treatment by community physicians.

S L McFall 1, R B Warnecke 1, A D Kaluzny 1, L Ford 1
PMCID: PMC1070100  PMID: 8617610

Abstract

OBJECTIVE. This article compares judgments about the treatment of Dukes' B2 and C colon cancer made by general surgeons to those of internists and family practitioners. Physician and practice variables were specialty, affiliation with a Community Clinical Oncology Program (CCOP) hospital, time in practice, professional centrality (level of participation in cancer information networks), solo practice, and number of colon cancer patients. DATA COLLECTION METHODS. Data are combined from national probability samples of CCOP- and non-CCOP-affiliated physicians. This study focused on 1,138 internists, family physicians, and general surgeons who participated in decision making for patients diagnosed with Dukes' B2 or C stage colon cancer. Judgments were elicited using brief vignettes. METHODS OF ANALYSIS. Judgments of adjuvant therapy are classified as (a) consistent with the National Institutes of Health Consensus Conference recommendations (experimental for Dukes' B2, accepted for Dukes' C); (b) accepted treatment for both stages; or (c) experimental for both stages. Multinomial logit analyses were used to examine the association of practice setting and physician characteristics to judgments of treatment. RESULTS. Surgeons and CCOP-affiliated physicians were more likely to endorse the NIH consensus conference position. Surgeons, younger physicians, and those in group practice were more likely to approve of chemotherapy for both cancer stages. The most common position (chemotherapy experimental) was more likely from nonsurgeons, solo practitioners, and non-CCOP physicians. CONCLUSION. Physician and practice setting characteristics, including organized structures such as the CCOP, are possible mediating structures that can facilitate dissemination of standards of treatment.

Full text

PDF
5

Images in this article

14Figure 1
on p.14

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buyse M., Zeleniuch-Jacquotte A., Chalmers T. C. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA. 1988 Jun 24;259(24):3571–3578. [PubMed] [Google Scholar]
  2. Chu K. C., Tarone R. E., Chow W. H., Hankey B. F., Ries L. A. Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J Natl Cancer Inst. 1994 Jul 6;86(13):997–1006. doi: 10.1093/jnci/86.13.997. [DOI] [PubMed] [Google Scholar]
  3. DUKES C. E. Discussion on major surgery in carcinoma of the rectum with or without colostomy, excluding the anal canal and including the rectosigmoid: general results of surgical treatment. Proc R Soc Med. 1957 Dec;50(12):1031–1035. doi: 10.1177/003591575705001212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Freiman M. P. The rate of adoption of new procedures among physicians. The impact of specialty and practice characteristics. Med Care. 1985 Aug;23(8):939–945. doi: 10.1097/00005650-198508000-00001. [DOI] [PubMed] [Google Scholar]
  5. Gilbert J. M. Trials of adjuvant chemotherapy in colorectal cancer. Drugs Exp Clin Res. 1986;12(1-3):201–210. [PubMed] [Google Scholar]
  6. Grilli R., Apolone G., Marsoni S., Nicolucci A., Zola P., Liberati A. The impact of patient management guidelines on the care of breast, colorectal, and ovarian cancer patients in Italy. Med Care. 1991 Jan;29(1):50–63. doi: 10.1097/00005650-199101000-00005. [DOI] [PubMed] [Google Scholar]
  7. Kaluzny A. D., Lacey L. M., Warnecke R., Morrissey J. P., Sondik E. J., Ford L. Accrual of patients to randomized clinical trials. Factors affecting cancer prevention and control research. Int J Technol Assess Health Care. 1994 Summer;10(3):506–516. doi: 10.1017/s0266462300006723. [DOI] [PubMed] [Google Scholar]
  8. Kaluzny A. D., Ricketts T., 3rd, Warnecke R., Ford L., Morrissey J., Gillings D., Sondik E. J., Ozer H., Goldman J. Evaluating organizational design to assure technology transfer: the case of the Community Clinical Oncology Program. J Natl Cancer Inst. 1989 Nov 15;81(22):1717–1725. doi: 10.1093/jnci/81.22.1717. [DOI] [PubMed] [Google Scholar]
  9. Kaluzny A. D., Warnecke R., Lacey L. M., Johnson T., Gillings D., Ozer H. Using a community clinical trials network for treatment, prevention, and control research: assuring access to state-of-the-art cancer care. Cancer Invest. 1995;13(5):517–525. doi: 10.3109/07357909509024917. [DOI] [PubMed] [Google Scholar]
  10. McFall S. L., Warnecke R. B., Kaluzny A. D., Aitken M., Ford L. Physician and practice characteristics associated with judgments about breast cancer treatment. Med Care. 1994 Feb;32(2):106–117. doi: 10.1097/00005650-199402000-00002. [DOI] [PubMed] [Google Scholar]
  11. Moertel C. G., Fleming T. R., Macdonald J. S., Haller D. G., Laurie J. A., Goodman P. J., Ungerleider J. S., Emerson W. A., Tormey D. C., Glick J. H. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990 Feb 8;322(6):352–358. doi: 10.1056/NEJM199002083220602. [DOI] [PubMed] [Google Scholar]

Articles from Health Services Research are provided here courtesy of Health Research & Educational Trust

RESOURCES